James C. Mathews
Memorial Sloan Kettering Cancer Center
28 Papers
39 Citations
James C. Mathews is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Population & Biological network. The author has an hindex of 4, co-authored 24 publications. Previous affiliations of James C. Mathews include Stony Brook University.
Chat about Author
Papers
Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes
James C. Mathews,Saad Nadeem,Arnold J. Levine,Maryam Pouryahya,Joseph O. Deasy,Allen Tannenbaum +5 more
- 09 Sep 2019
TL;DR: The Normal class shows similarity with the myoepithelial mammary cell phenotype, including TP63 expression, and exhibits the best overall survival, while tumors in the luminal class (concordant with Luminal A) may be more aggressive than previously thought.
Functional network analysis reveals an immune tolerance mechanism in cancer.
James C. Mathews,Saad Nadeem,Maryam Pouryahya,Zehor Belkhatir,Joseph O. Deasy,Arnold J. Levine,Allen Tannenbaum +6 more
TL;DR: A technique to construct a simplification of a feature network which can be used for interactive data exploration, biological hypothesis generation, and the detection of communities or modules of cofunctional features, which implicate the PSGs in a potential immune tolerance mechanism of cancers.
19
Characterizing Cancer Drug Response and Biological Correlates: A Geometric Network Approach
TL;DR: The study suggests that utilization of mathematical tools for network-based analysis can provide novel insights into drug response and cancer biology, and adopts a discrete notion of Ricci curvature to measure the robustness of biological networks constructed with a pre-treatment gene expression dataset.
17
Pan-Cancer Prediction of Cell-Line Drug Sensitivity Using Network-Based Methods
Maryam Pouryahya,Jung Hun Oh,James C. Mathews,Zehor Belkhatir,Caroline Moosmüller,Joseph O. Deasy,Allen Tannenbaum +6 more
TL;DR: A novel network-based methodology is proposed that breaks the problem into smaller, more interpretable problems to improve the predictive power of anti-cancer drug responses in cell lines and finds that among the four drugs top-ranked with respect to prediction performance, three targeted the PI3K/mTOR signaling pathway.
Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.
Rami Vanguri,Kathleen Fenn,Matthew R. Kearney,Qi Wang,Hua Guo,Douglas K. Marks,Christine Chin,Claire F. Alcus,Jay Thompson,Cheng-Shiun Leu,Hanina Hibshoosh,Kevin Kalinsky,James C. Mathews,Saad Nadeem,Travis J. Hollmann,Eileen P. Connolly +15 more
TL;DR: In this article , the authors used standard stromal pathologist-assessed tumor infiltrating lymphocyte (TIL) quantification, quantitative multiplex immunofluorescence, and RNA-based gene pathway signatures to assess pretreatment TME characteristics associated pathologic complete response in patients with hormone receptor positive, HER2 positive early breast cancer treated in the neoadjuvant setting.
11